Effects On Growth And Development Of Extremely Premature Infants With Combined Clostridium Butyricum And Bifidobacterium

Objective:To investigate the safety of Combined Clostridium butyricum and Bifidobacterium that was applied to very preterm infants by observing the incidence of adverse reactions.And to explore the role of Combined Clostridium butyricum and Bifidobacterium in reducing the risk of late sepsis,neonatal necrotizing enterocolitis,feeding intolerance and promoting growth and development of very preterm infants.In addition,to evaluate the effectiveness of its application in very premature infants.Methods:A total of 60 eligible premature infants admitted to the Department of Neonatology,the First Affiliated Hospital of Wannan Medical College were collected with informed consent from their families in the range of April 2021 to November 2022,including 30 in the experimental group and 30 in the control group.According to the random number table method,the eligible very premature infants were divided into the experimental group and the control group.The experimental group began to take probiotics after milk opening(no later than 1 week after birth),once in the morning and evening respectively for 4 weeks,while the control group did not take probiotics.Parenteral nutrition is administered 100-120 m L/(kg·d)pasteurized breast milk(HM)or formula to intestines for premature infants.The general condition,incidence of adverse reactions,length of total enteral feeding,length of hospital stay,gestational age at discharge,length of 28 days after birth,head circumference,average growth rate of body mass,feeding intolerance,incidence of NEC and late onset sepsis,incidence of extrauterine growth retardation and growth and development Z score of the two groups were observed.Analyze whether there are differences between the indicators or not.SPSS25.0 statistical software was used for data processing,measurement data was expressed as mean ± standard deviation,comparison between two groups was expressed as t test,count data was expressed as number of cases and percentage(%),comparison between two groups was performed as Chi-square test,P<0.05.Results: There were no statistically significant differences between the two groups in gender,gestational age,delivery mode,feeding mode,birth weight,length of admission,head circumference,5-minute Apgar score and maternal diseases during pregnancy(P>0.05).In terms of clinical indicators,the experimental group was smaller than the control group in total intestinal feeding,length of stay and gestational age at discharge.There was statistical difference(P<0.05).After 28 days of hospitalization,the average growth rate of body length,head circumference and body mass of the experimental group were significantly increased compared with the control group,with statistical differences(P<0.05).Z-values of discharged body length,head circumference and body mass in the experimental group were higher than those in the control group,and there were statistical differences between the two groups(P<0.05).In a comparison of the incidence of complications in preterm infants,there were 7 cases of feeding intolerance,1 cases of neonatal necrotizing enterocolitis,1 case of late-onset septicemia,8 cases of bronchopulmonary dysplasia,5 cases of extra-uterine growth retardation and 10 cases of intraventricular hemorrhage in the experimental group and there were 15 cases of feeding intolerance,1 cases of necrotizing enterocolitis,1 case of late-onset septicemia,16 cases of bronchopulmonary dysplasia,12 cases of extrauterine growth retardation and 13 cases of intraventricular hemorrhage in the control group,which compared with the incidence of complications in preterm infants.There were statistical differences between the two groups in the incidence of feeding intolerance,bronchopulmonary dysplasia and extrauterine growth retardation(P<0.05),but no statistical differences in the incidence of neonatal necrotizing enterocolitis,late-onset sepsis and intraventricular hemorrhage(P>0.05).Conclusions:1.Combined Clostridium butyricum and Bifidobacterium can shorten the total enteral nutrition time and hospital stay for very premature infants,increase the growth speed of body length,body weight and head circumference,improve the Z score of growth and development,and promote the growth and development of very premature infants.2.Combined Clostridium butyricum and Bifidobacterium can reduce the incidence of feeding intolerance,bronchopulmonary dysplasia and extrauterine growth retardation in very premature infants.3.The Combined Clostridium butyricum and Bifidobacterium has no adverse reaction during the treatment,and it is safe to use in very premature infants.